Michael Gibney from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Michael Gibney Pharma Voice		By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - 20 days ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 22 days ago Subcutaneous options offer convenience for patients — and a valuable window for drugmakers - 29 days ago 4 closely watched FDA approval dates in 2025 from J&J, Novo and more - about 1 month ago How pharma was instrumental in President Jimmy Carter’s global health efforts - about 1 month ago Maternal mortality trends remain dire — and researchers face an uphill battle to solve them - about 2 months ago Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - about 2 months ago GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback. - about 2 months ago How Astellas juggles the moving parts of cancer precision medicine development - 2 months ago How Alexion markets a rare disease drug by ‘starting with the end in mind’ - 2 months ago Specialized CROs aim to boost participation among women and other underrepresented groups - 2 months ago How the incoming administration could impact FTC’s approach to pharma M&A - 2 months ago An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 2 months ago Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals - 3 months ago What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine - 3 months ago Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug - 3 months ago Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past - 3 months ago Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in - 3 months ago Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 3 months ago 2024 PharmaVoice 100s: Cancer Care Visionaries - 3 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 3 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 3 months ago How AZ’s respiratory wins are ramping up for a bigger prize in COPD - 3 months ago Why pharma megamergers may become a relic of the past - 3 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 4 months ago With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble - 4 months ago As new Alzheimer’s biomarkers come into play, here’s where the money is going - 4 months ago AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential - 4 months ago Will a Medicare boost propel digital therapeutics to the mainstream? - 4 months ago Flu vaccination rates are falling despite record child deaths. Can innovation save the day? - 4 months ago Top pharma and biotech conferences 2025 - 4 months ago How Lilly’s sustainability goals come face to face with massive growth - 5 months ago A new way of determining a drug’s value — with health equity in mind - 5 months ago Huntington’s disease R&D is regaining ground after several disappointments - 5 months ago Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that. - 5 months ago A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market - 5 months ago Their Alzheimer’s treatment worked — but shares fell anyway - 5 months ago Will the IRA squash new drugs? Those worries are likely exaggerated, studies say. - 6 months ago 23andMe inches closes to cancer immunotherapy, guided by its genetic database - 6 months ago Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through - 6 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 6 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 6 months ago A biotech dousing ‘fires’ in the brain that plagued a bestselling author - 6 months ago Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback - 6 months ago 7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run - 6 months ago Gilead eyes ‘ending the HIV epidemic’ via incremental progress - 7 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 7 months ago Has pharma emerged from the ‘age of uncertainty’? - 7 months ago As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat - 7 months ago The FDA pushes concrete plans to further diversity in clinical trials - 7 months ago